iopamidol (Rx)

  • Print
Brand and Other Names:Isovue, Scanlux

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

Content expressed as organic bound iodine/mL

injectable solution

  • 200mg/mL (41%)
  • 300mg/mL (61%)

intravenous solution

  • 200mg/mL (41%)
  • 250mg/mL (51%)
  • 300mg/mL (61%)
  • 370mg/mL (76%)
more...

Angiography

Cerebral Arteriography

  • 300 mg/mL: 8-12 mL intra-arterial, may repeat, not to exceed 90 mL

Peripheral Venography

  • 200 mg/mL: 25-150 mL IV per lower extremity; total not to exceed 350 mL

Coronary Arteriography

  • 370 mg/mL: 2-10 mL IV; monitor EKG; not to exceed 200 mL

Coronary Ventriculography

  • 370 mg/mL: 25-50 mL IV; monitor EKG; not to exceed 200 mL

Selective Visceral Arteriography

  • 370 mg/mL: Up to 50 mL IV; not to exceed 225 mL

Selective Visceral Aortography

  • 370 mg/mL: Up to 50 mL IV; not to exceed 225 mL

Peripheral Venography

  • 200 mg/mL: 25-150 mL; not to exceed 350 mL

Computed Tomography

CECT of the Head

  • 250 mg/mL: 130-240 mL IV; not to exceed 240 mL
  • Alternatively, 300 mg/mL: 100-200 mL IV; not to exceed 200 mL
  • Imaging may be done immediately after completing administration

CECT of the Body

  • 250 mg/mL: 130-240 mL IV; not to exceed 240 mL
  • Alternatively, 300 mg/mL: 100-200 mL IV; not to exceed 200 mL
  • Imaging may be done immediately after completing administration

Urography

Excretory Urography

  • 250 mg/mL: 50-100 mL IV OR
  • 300 mg/mL: 50 mL IV OR
  • 370 mg/mL: 40 mL IV

Dosage Forms & Strengths

Content expressed as iodine/mL

injectable solution

  • 200mg/mL (41%)
  • 300mg/mL (61%)

intravenous solution

  • 200mg/mL (41%)
  • 250mg/mL (51%)
  • 300mg/mL (61%)
  • 370mg/mL (76%)
more...

Angiocardiography

For 370 mg/mL:

<2 years: 10-15 mL IV, not to exceed 40 mL total

2-9 years: 15-30 mL IV, not to exceed 50 mL (2-4 years) or 100 mL (5-9 years)

10-18 years: 20-50 mL IV, not to exceed 125 mL

Computed Tomography

CECT of the Head

  • 250 mg/mL: 1.2-3.6 mL/kg IV; not to exceed 30 g of iodine
  • Alternatively, 300 mg/mL: 1-3 mL/kg IV; not to exceed 30 g of iodine

CECT of the Body

  • 250 mg/mL: 1.2-3.6 mL/kg IV; not to exceed 30 g of iodine OR
  • 300 mg/mL: 1-3 mL/kg IV; not to exceed 30 g of iodine

Urography

Excretory Urography

  • 250 mg/mL: 1.2-3.6 mL/kg IV; not to exceed 30 g of iodine OR
  • 300 mg/mL: 1-3 mL/kg IV; not to exceed 30 g of iodine
Next:

Adverse Effects

1-10%

Hot flashes (3.4%)

Angina pectoris (3%)

Flushing (1.8%)

Bradycardia (1.3%)

Hypotension (1%)

Hives (1%)

<1%

Cyanotic heart disease

Right ventricular abnormalities

Abnormal pulmonary circulation

Previous
Next:

Warnings

Black Box Warnings

Not for intrathecal use

Contraindications

Hypersensitvity to product or components

Intrathecal injection concurrently with intrathecal corticosteroid administration (significant bacterial infection)

Cautions

Before examination patients should be well hydrated to prevent contrast associated nephropathy

Caution in patients with seizures, thromboembolic diseases including IM and stroke, chronic alcoholism, heart failure, hepatorenal insufficiency, hyperthyroidism, multiple myeloma, pheochromocytoma, renal disease, sickle cell disease

Serious adverse events reported from inadvertent intrathecal administration of iodinated contrast that is not indicated for intrathecal use (Isovue and Isovue Miltipack are not for intrathecal administration)

Hypothyroidism and transient thyroid suppression reported

Previous
Next:

Pregnancy & Lactation

Pregnancy Category: B

Lactation: Excretion into breast milk unknown; not recommended

Pregnancy Categories

A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA:Information not available.

more...
Previous
Next:

Pharmacology

Mechanism of Action

Radiographic visualization achieved through the opacification of vessels and anatomical structures in the path of flow of the contrast media

Pharmacokinetics

Half-life: 2 hr; prolonged in renal impairment

Excretion: Urine (80-90%)

Previous
Next:

Images

Previous
Next:

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Additional Offers
Email to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Email Forms to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Previous